Marty Solomon, MD reviews BRONCHITOL and its key clinical and safety data.
Marty Solomon, MD, Pulmonologist and Director of the Adult CF Clinic at the Univeristy of Alabama at Birmingham, explains what BRONCHITOL therapy is and how to administer it.
Lauren Cardoni, FNP-C at Bringam and Woman's Hospital in Boston, discusses the BRONCHITOL Tolerance Test, its purpose, and the steps to follow while conducting it.
Dr. Marty Solomon reviews key information that HCP's should know when starting a patient on BRONCHITOL.
Lauren Cardoni talks about Chiesi CareDirect, a program that offers multiple support services for eligible patients, including prescription access and financial assistance.†
†Restrictions apply. Please refer to the full Terms and Conditions for all eligibility requirements.
Watch this video to learn more about BRONCHITOL, the BTT, and dosing and to get helpful tips on how to take BRONCHITOL.
Download Patient Profiles*
*Not actual patients. Patient symptoms will vary; individual evaluation should be done to determine best course of therapy.
Request additional information or to be contacted by a Chiesi sales representative
BRONCHITOL is contraindicated in patients with hypersensitivity to mannitol or to any of the capsule components. BRONCHITOL is contraindicated in patients who fail to pass the BRONCHITOL Tolerance Test (BTT).
BRONCHITOL can cause bronchospasm, which can be severe in susceptible patients. Because of the risk of bronchospasm, prior to prescribing BRONCHITOL, patients must pass the BRONCHITOL Tolerance Test (BTT). The BTT must be administered under the supervision of a healthcare practitioner who can treat severe bronchospasm.
Patients who pass the BRONCHITOL tolerance test (BTT) may experience bronchospasm with add-on maintenance therapy with BRONCHITOL. Patients should premedicate with an inhaled short-acting bronchodilator prior to each administration of BRONCHITOL. If bronchospasm occurs, immediately discontinue BRONCHITOL and treat bronchospasm with an inhaled short-acting bronchodilator.
Hemoptysis can occur with BRONCHITOL use. Monitor patients with history of episodes of hemoptysis. If hemoptysis occurs, discontinue use of BRONCHITOL.
Most common adverse reactions (≥3%) include cough, hemoptysis, oropharyngeal pain, vomiting, bacteria sputum identified, pyrexia, and arthralgia.
BRONCHITOL® (mannitol) inhalation powder is a sugar alcohol indicated as add-on maintenance therapy to improve pulmonary function in adult patients 18 years of age and older with cystic fibrosis. Use BRONCHITOL only in adults who have passed the BRONCHITOL Tolerance Test.